Blereau RP, 1980. Septicemia and death caused by Chromobacterium violaceum. South Med J 73: 1093–1094.
McGloughlin S, Richards GA, Nor MBM, Prayag S, Baker T, Amin P, 2017. Sepsis in tropical regions: report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care 46: 115–118.
Slesak G, Douangdala P, Inthalad S, Silisouk J, Vongsouvath M, Sengduangphachanh A, Moore CE, Mayxay M, Matsuoka H, Newton PN, 2009. Fatal Chromobacterium violaceum septicaemia in northern Laos, a modified oxidase test and post-mortem forensic family G6PD analysis. Ann Clin Microbiol Antimicrob 8: 24.
Yang CH, Li YH, 2011. Chromobacterium violaceum infection: a clinical review of an important but neglected infection. J Chin Med Assoc 74: 435–441.
Macher AM, Casale TB, Fauci AS, 1982. Chronic granulomatous disease of childhood and Chromobacterium violaceum infections in the southeastern United States. Ann Intern Med 97: 51–55.
Madi DR, Vidyalakshmi K, Ramapuram J, Shetty AK, 2015. Successful treatment of Chromobacterium violaceum sepsis in a south Indian adult. Am J Trop Med Hyg 93: 1066–1067.
Victorica B, Baer H, Ayoub EM, 1974. Successful treatment of systemic Chromobacterium violaceum infection. JAMA 230: 578–580.
Censusdata.abs.gov.au, 2018. 2016 Census QuickStats: Cairns. Available at: http://www.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/306?opendocument. Accessed March 7, 2018.
Censusdata.abs.gov.au, 2018. 2016 Census QuickStats: Far North. Available at: http://www.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/31501?opendocument. Accessed March 7, 2018.
Lin Y, Majumdar SS, Hennessy J, Baird RW, 2016. The spectrum of Chromobacterium violaceum infections from a single geographic location. Am J Trop Med Hyg 94: 710–716.
Therapeutic Guidelines, 2015. eTG Complete. Melbourne, Australia: Therapeutic Guidelines Limited.
Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R, 2014. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311: 1308–1316.
Edmiston CE, Garcia R, Barnden M, DeBaun B, Johnson HB, 2018. Rapid diagnostics for bloodstream infections: a primer for infection preventionists. Am J Infect Control, doi: 10.1016/j.ajic.2018.02.022.
Rhodes A et al. 2017. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43: 304–377.
Dellinger RP et al. 2004. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32: 858–873.
Miki T, 2014. Virulence determinant of Chromobacterium violaceum. Nihon Saikingaku Zasshi 69: 577–588.
Miller DP, Blevins WT, Steele DB, Stowers MD, 1988. A comparative study of virulent and avirulent strains of Chromobacterium violaceum. Can J Microbiol 34: 249–255.
Pant ND, Acharya SP, Bhandari R, Yadav UN, Saru DB, Sharma M, 2017. Bacteremia and urinary tract infection caused by Chromobacterium violaceum: case reports from a Tertiary Care Hospital in Kathmandu, Nepal. Case Rep Med 2017: 7929671.
Hagiya H, Murase T, Suzuki M, Shibayama K, Kokumai Y, Watanabe N, Maki M, Otsuka F, 2014. Chromobacterium violaceum nosocomial pneumonia in two Japanese patients at an intensive care unit. J Infect Chemother 20: 139–142.
Swain B, Otta S, Sahu KK, Panda K, Rout S, 2014. Urinary tract infection by Chromobacterium violaceum. J Clin Diagn Res 8: Dd01–Dd02.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 701 | 507 | 53 |
Full Text Views | 563 | 10 | 1 |
PDF Downloads | 193 | 11 | 0 |
In many parts of the world, the case-fatality rate of Chromobacterium violaceum infection approaches 60%. To evaluate the spectrum of disease associated with C. violaceum in Far North Queensland (FNQ), Australia, we reviewed all culture-confirmed isolates from 1997 to 2017. There were 28 isolates, 15 represented infection, 11 were contaminants, and two charts were destroyed preventing detailed evaluation of these cases. The most common sites of infection were the skin and soft tissue and the urinary tract; there were two cases of bacteremia without focus. There were no deaths attributable to C. violaceum during the study period and only two cases required intensive care unit support, although in both patients this was not for the C. violaceum infection, but for the management of other health issues. Globally, C. violaceum has a reputation as a deadly pathogen, but in FNQ, Australia, infections usually follow a relatively benign course.
Authors’ addresses: Alice Young, Intensive Care, Cairns Hospital, Cairns, Australia, E-mail: alice.young@health.qld.gov.au. Simon Smith, Department of Medicine, Cairns Hospital, Cairns, Australia, E-mail: simon.smith2@health.qld.gov.au. Peter Horne, Tropical Public Health Unit, Cairns and Hinterland Hospital and Health Service, Cairns, Australia, E-mail: peter.horne@health.qld.gov.au. Bronwyn Thomsett, Pathology Department, Cairns Hospital, Cairns, Australia, E-mail: bronwyn.thomsett@health.qld.gov.au. Josh Hanson, The Kirby Institute, University of New South Wales, Sydney, Australia, and General Medicine, Cairns Hospital, Cairns, Australia, E-mail: jhanson@kirby.unsw.edu.au.
Blereau RP, 1980. Septicemia and death caused by Chromobacterium violaceum. South Med J 73: 1093–1094.
McGloughlin S, Richards GA, Nor MBM, Prayag S, Baker T, Amin P, 2017. Sepsis in tropical regions: report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care 46: 115–118.
Slesak G, Douangdala P, Inthalad S, Silisouk J, Vongsouvath M, Sengduangphachanh A, Moore CE, Mayxay M, Matsuoka H, Newton PN, 2009. Fatal Chromobacterium violaceum septicaemia in northern Laos, a modified oxidase test and post-mortem forensic family G6PD analysis. Ann Clin Microbiol Antimicrob 8: 24.
Yang CH, Li YH, 2011. Chromobacterium violaceum infection: a clinical review of an important but neglected infection. J Chin Med Assoc 74: 435–441.
Macher AM, Casale TB, Fauci AS, 1982. Chronic granulomatous disease of childhood and Chromobacterium violaceum infections in the southeastern United States. Ann Intern Med 97: 51–55.
Madi DR, Vidyalakshmi K, Ramapuram J, Shetty AK, 2015. Successful treatment of Chromobacterium violaceum sepsis in a south Indian adult. Am J Trop Med Hyg 93: 1066–1067.
Victorica B, Baer H, Ayoub EM, 1974. Successful treatment of systemic Chromobacterium violaceum infection. JAMA 230: 578–580.
Censusdata.abs.gov.au, 2018. 2016 Census QuickStats: Cairns. Available at: http://www.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/306?opendocument. Accessed March 7, 2018.
Censusdata.abs.gov.au, 2018. 2016 Census QuickStats: Far North. Available at: http://www.censusdata.abs.gov.au/census_services/getproduct/census/2016/quickstat/31501?opendocument. Accessed March 7, 2018.
Lin Y, Majumdar SS, Hennessy J, Baird RW, 2016. The spectrum of Chromobacterium violaceum infections from a single geographic location. Am J Trop Med Hyg 94: 710–716.
Therapeutic Guidelines, 2015. eTG Complete. Melbourne, Australia: Therapeutic Guidelines Limited.
Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R, 2014. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311: 1308–1316.
Edmiston CE, Garcia R, Barnden M, DeBaun B, Johnson HB, 2018. Rapid diagnostics for bloodstream infections: a primer for infection preventionists. Am J Infect Control, doi: 10.1016/j.ajic.2018.02.022.
Rhodes A et al. 2017. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43: 304–377.
Dellinger RP et al. 2004. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32: 858–873.
Miki T, 2014. Virulence determinant of Chromobacterium violaceum. Nihon Saikingaku Zasshi 69: 577–588.
Miller DP, Blevins WT, Steele DB, Stowers MD, 1988. A comparative study of virulent and avirulent strains of Chromobacterium violaceum. Can J Microbiol 34: 249–255.
Pant ND, Acharya SP, Bhandari R, Yadav UN, Saru DB, Sharma M, 2017. Bacteremia and urinary tract infection caused by Chromobacterium violaceum: case reports from a Tertiary Care Hospital in Kathmandu, Nepal. Case Rep Med 2017: 7929671.
Hagiya H, Murase T, Suzuki M, Shibayama K, Kokumai Y, Watanabe N, Maki M, Otsuka F, 2014. Chromobacterium violaceum nosocomial pneumonia in two Japanese patients at an intensive care unit. J Infect Chemother 20: 139–142.
Swain B, Otta S, Sahu KK, Panda K, Rout S, 2014. Urinary tract infection by Chromobacterium violaceum. J Clin Diagn Res 8: Dd01–Dd02.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 701 | 507 | 53 |
Full Text Views | 563 | 10 | 1 |
PDF Downloads | 193 | 11 | 0 |